Fraud Claims Against Lilly Tossed In Cymbalta Labeling Row

Law360, New York (August 28, 2015, 2:13 PM EDT) -- A Virginia federal judge on Friday found that two women suing Eli Lilly and Co. for allegedly misrepresenting the withdrawal risks of its antidepressant drug Cymbalta had failed to present enough jury evidence to support their fraud claims, tossing them from court but keeping alive a negligence allegation.

U.S. District Judge Anthony J. Trenga issued his bench order on Friday morning after plaintiffs Gilda Hagan-Brown and Janine Ali wrapped up four days of evidence presentation to a Virginia federal jury on Thursday, granting a motion for judgment as a matter of law by Lilly filed late Thursday night, and deciding not to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies